Introduction
Down syndrome (DS) is most commonly caused by duplication of one of the copies of chromosome 21, resulting in trisomy for this chromosome. DS patients are characterised by mental impairment that is frequently associated with dysmorphic features, cardiac abnormalities, early onset Alzheimer disease, gonadal deficiency, and an increased risk for certain leukaemias and immunological deficiencies. 1 Recent advances in the treatment for these patients have resulted in an increase in the average life span in DS that has allowed an evaluation of solid tissue cancer incidence, which more commonly occur in aged populations. Surprisingly, although some types of cancer (particularly many types of leukaemia, gonadal, and soft tissue cancers) are relatively more common, solid tumours as a whole have been found to have a decreased incidence in DS. 2 ± 4 This finding has led to the speculation of possible`tumour suppressor' genes for solid tumours on chromosome 21. 2 ± 5 Indeed, loss of heterozygosity has been observed for specific regions of chromosome 21 in several solid tumours. 6 ± 8 However, although chromosome 21 has been completely sequenced, no recognised tumour suppressor genes have yet been described. 5 We hypothesise that the decreased incidence of solid tumours in individuals with DS may be due to increased dosage of one or more chromosome 21 gene products that might participate in a common mechanism involved in the growth of various solid tumours. Endostatin is a soluble 20 kd cleavage product of collagen XVIII, which is encoded by the COL18A1 gene at 21q22.3.
9,10
It has recently been shown that endostatin is a potent angiogenesis inhibitor for many different types of solid tissue tumours in both human and animal models. Endostatin is also currently being aggressively pursued as a candidate for cancer therapy in humans. 9, 11, 12 The COL18A1 gene was found to be widely expressed in mice and humans. 10, 13, 14 The production and liberation of endostatin is still poorly understood, but it has been found to be expressed in some differentiated tissues (eg kidney and liver) and freely circulating in serum. 9, 15, 16 These observations, combined with the emerging data on endostatin as a potential tumour angiogenesis inhibitor prompted us to verify whether patients with DS had an increased serum level of endostatin compared with normal control subjects.
Materials and methods

Human subjects
All human subjects used for this study were enrolled voluntarily, under their own consent or with the consent of responsible family members when appropriate (ie for minors and patients with DS Clinical data from most of these patients are described in Table 1 . Blood samples were collected by venipuncture in EDTA containing tubes, always in the morning, and serum was separated and stored at 7708C for future use.
ELISA ELISA for serum endostatin was performed using a commercially available assay (Accucyte, Cytimmune Sciences, Inc., College Park, MD, USA) according to the manufacturer's instructions for usage. All measurements were performed in duplicate to ensure the accuracy of the data collected. The kit used has a sensitivity of 2 ng/ml, and typical interassay and intra-assay variances were 10% or less. Readings were performed on a Titertek Multiskan PLUS plate reader (EFLAB, Finland) at 492 nm wavelength according to the manufacturer's instructions.
Statistical analysis
Statistical analysis of the serum endostatin levels from patients and control subjects was analysed using the program JMP running on an Apple Macintosh G3 computer.
Results
We observed that endostatin levels vary widely among normal individuals, ranging from 4 to 40 ng/ml ( Figure 1 ; Table 1 ). We found a highly significant difference in the average serum endostatin concentration between Down syndrome and control subjects (38.6+20.1 for DS, 20.3+11.5 for normal subjects, data reported as mean+SD in ng/ml; P50.0001 by Wilcoxon/ Kruskal-Wallis tests; see Figure 1 and Tables 1 and 2 ). Statistical analysis revealed no significant difference in endostatin levels by sex for either the control group or DS population (F ratio 0.4141, P40.05 for both groups; see Table 2 ). The average age for the control group was 17.9+12.9 years, while for the DS patients the average age was 11.4+4.6 years. Linear regression of endostatin levels with age in the control group and patient population studied revealed no significant correlation of endostatin level with age (F ratio 3.875, P40.05 for both groups). Therefore, based upon the data presented in Figure 1 and Tables 1 and 2 , we demonstrate that serum levels of 
Discussion
The great variability of endostatin levels found both in controls and DS patients is in agreement with previous measurements of serum endostatin. 17 ± 19 We did not observe any effect of sex or age in serum endostatin levels both in controls and in DS patients, a finding that has not previously been reported.
Given the recent profusion of data about the effectiveness of endostatin as an antitumour agent in both human subjects and animal models, we propose that elevated serum levels of endostatin present in the serum of patients with DS might explain the relatively low incidence of many different types of solid tissue tumours in these patients.
Our data are compatible with recent experiments in mouse models, which showed that persistently high serum levels of endostatin resulted in a significant reduction of the tumour growth rate and in the prevention of micrometastases of some carcinomas. 11, 12 Based upon data presented here, we
propose that an increase of about one-third of endostatin serum levels would be sufficient to significantly inhibit many solid tumour cancers. These results also predict that individuals in the population with serum endostatin levels higher than 20 ng/ml might be less prone for the development of solid tumours than those with lower levels and therefore, it will be important to evaluate the use of endostatin levels as a predictive test. It has recently been shown that reduced endostatin levels correlate with increased tumour size and higher histological grade of some types of tumour, thus reinforcing our hypothesis. 17, 18 Recently, several reports have been published about the mechanism of action of endostatin as an anti-angiogenesis and tumour suppressor reagent. 20 were able to further demonstrate that endostatin application downregulates genes expressed during endothelial cell growth, and exhibited a potent antimigratory effect on endothelial cells in vitro, mediated through c-myc downregulation. Most recently, Karumanchi et al 22 were able to use expression cloning to identify cell surface glypicans as a low affinity receptor for endostatin. Glypicans were shown to have functional relevance in antisense experiments using kidney cell lines, and in addition were also demonstrated to be highly expressed in epithelial cells. 22 Therefore, taking together recent evidence, we can hypothesise that endostatin acts upon one or more receptors present on endothelial cells, resulting in intracellular signalling which decreases the migratory capacity and/or proliferative ability of endothelial cells, which prevents new vascularisation in the presence of high endostatin activity. We further propose that rodent models of DS that would express elevated serum levels of endostatin could be used to test our hypothesis with regard to tumour incidence, and to test for any possible toxic effects of persistently high endostatin levels. High levels of circulating endostatin have been found in patients with Systemic Sclerosis, but it is still unclear if increased endostatin production is primary or secondary to the vascular injuries responsible for this condition. 19 However, the elevated levels of endostatin found to associate with Systemic Sclerosis were five times Figure 1 Endostatin serum levels in DS patients (D) and control subjects (C), which were determined through ELISA using a commercially available assay (Accucyte, Cytimmune Sciences, Inc., College Park, MD, USA). Dark horizontal bar represents the mean of endostatin levels; grey horizontal bar represents the standard deviation of endostatin values. High serum endostatin levels in Down syndrome TS Zorick et algreater than the normal subject controls, whereas in our study the increase in circulating endostatin in DS was much more modest. 19 Despite the potential caveats, we believe that confirmation of a role for elevated serum endostatin levels as a protective agent for the lifelong development of solid tumours may lead to further advances in the understanding of endostatin antitumour activity and to improvement in cancer treatment.
